Aquestive Q3 Revenue Falls 41% to $7.6M; Anaphylm PDUFA Set for March 16, 2027
AQST sits 26% above its 52-week low of $2.93.
Summary
Aquestive reported Q3 2026 revenue of $7.6M, down 41% on Suboxone order timing, and a $16.5M net loss, while keeping 2026 guidance unchanged and confirming the Anaphylm PDUFA date of March 16, 2027.
Key Events · Earnings and Guidance · AQST
-
Q3 Revenue Falls 41%
Total revenues were $7.6M versus $12.8M in Q3 2025, driven by quarterly fluctuation of Suboxone product orders; manufacture and supply revenue fell to $6.7M from $11.5M.
-
Net Loss Widens to $16.5M
Net loss was $16.5M, or $0.13 per share, versus $15.4M, or $0.14 per share, a year earlier; non-GAAP adjusted EBITDA loss was $12.2M versus $8.6M.
-
Anaphylm PDUFA March 16, 2027
The FDA accepted the Anaphylm NDA resubmission as a Class 2 response with a PDUFA goal date of March 16, 2027; Health Canada submission is expected in Q4 2026 and an EU filing in Q1 2027.
-
Cash Falls to $90.3M
Cash and cash equivalents were $90.3M at September 30, 2026, down from $121.2M at December 31, 2025, after the $10M Libervant upfront from Eton Pharmaceuticals in October.
Analysis · AQST · Life Sciences
Revenue dropped 41% year over year to $7.6M because Suboxone orders landed in a different quarter, and the net loss widened to $16.5M from $15.4M. The quarter's real weight sits on Anaphylm: the FDA accepted the resubmission as a Class 2 response with a March 16, 2027 PDUFA date, and the company says launch preparations and a field sales build are on track. Cash fell to $90.3M from $121.2M at year-end, but the $10M Libervant upfront from Eton plus up to $47.5M in milestones and mid-teens royalties adds non-dilutive capital ahead of a potential launch. Full-year guidance was left unchanged at $46-$50M revenue and a $35-$30M adjusted EBITDA loss.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AQST was trading at $3.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $487M. The 52-week trading range was $2.93 to $6.85. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.